A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

85 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-03-20

Study Completion Date

2025-08-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of the study is to look at the effect of the study drug compared to placebo on calorie intake, energy metabolism, and appetite. The study will last up to 6 months and may include up to 20 visits.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of LY3437943 in Participants Who Have Obesity or Are Overweight

NCT04881760

Obesity Overweight

COMPLETED PHASE2

A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

NCT06230523

Obesity Overweight and Obesity

COMPLETED PHASE2

Methodology Study To Examine 6-Week Food Intake With Liraglutide In Obese Subjects

NCT03041792

Obesity

COMPLETED PHASE1

A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight

NCT06683508

Obesity Overweight

ACTIVE_NOT_RECRUITING PHASE2

A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight

NCT06124807

Obesity Overweight and Obesity

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Sponsor-blind

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LY3437943

LY3437943 administered subcutaneously (SC)

Group Type EXPERIMENTAL

LY3437943

Intervention Type DRUG

Administered SC

Placebo

Placebo administered SC

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Administered SC

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LY3437943

Administered SC

Intervention Type DRUG

Placebo

Administered SC

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* BMI greater than 30 kg/m2
* History of at least 1 self-reported unsuccessful dietary effort to reduce body weight

Exclusion Criteria

* Change in body weight of greater than 5 kg (11 pounds) within 3 months prior to start of study
* Any of the following treatments for obesity within 1 year prior, or plan to undergo any of these during the study period: liposuction, cryolipolysis, or abdominoplasty
* Prior or planned bariatric or gastric sleeve surgery, endoscopic therapy, or device-based therapy for obesity
* Type 1 or Type 2 Diabetes, history of ketoacidosis, or hyperosmolar state
* Family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome Type 2
* Acute or chronic hepatitis
* Had within 90 days prior: acute myocardial infarction, cerebrovascular accident (stroke), coronary artery revascularization, hospitalization for unstable angina, or hospitalization due to congestive heart failure
* History of active or unstable major depressive disorder or other severe psychiatric disorder within 2 years prior
* History of chronic or acute pancreatitis
* Blood transfusion or severe blood loss within the last 3 months or hemoglobinopathy, hemolytic anemia, sickle cell anemia
* Clinically significant multiple or severe drug allergies
* Started treatment with or changed dose within 12 months prior any medications that are associated with significant weight gain
* History of substance use disorder

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No